Next-Generation
Monoclonal Antibodies
Outstanding in silico human antibodies in 3–5 days — designed for your target, IP landscape, and downstream needs.
CONNECTED TO LEADING BIOTECH CLUSTERS
Product
Built for Outstanding Human Antibodies
There are over 1018 possible antibody sequences.
Generic protein large language models (LLMs) overlook critical antibody constraints, especially in the highly variable regions (CDRs), essential for antigen recognition and binding.Fabulous ᴬᴵ generates in silico human antibodies in 3–5 days — designed for your target, your IP landscape, and your downstream needs.Scientist-reviewed. Validation-ready.
Go from target to in vitro validation in days.
Day 1
Target Versatility
From viral surface proteins to cancer biomarkers, immunology markers, and membrane proteins—choose your target we analyze it together.
Day 3-4
Computational Pipelines
Starting with curated human sequences from quality-controlled databases, our service recursively improves antibodies through a validated approach. Our in silico maturation process mirrors natural human germinal center evolution, maximizing efficacy while minimizing adverse reaction risks.
Day 5
Next-Generation Monoclonal-Antibodies
Premium shortlist of 20 fully human monoclonal antibodies that fast-track clinical studies. Our product delivers superior thermostability, sequences validated by our scientific team, manufacturing readiness, and improved expression yields with minimal off-target binding. Future developments will further reduce cross-reactivity.
FEATURES
Starting with your Scientific Problem
Outstanding antibodies require to start with a scientific discussion in order to understand your challenges and scope what is possible now and on the long term.Fabulous ᴬᴵ is continuously pushed to offer a range of use cases to align to your reality.
INFUSING AI IN YOUR HIT IDENTIFICATION
Benefits of in silico Monoclonal Antibodies
in silico Speed
Design human mAbs in 3–5 days using known scaffolds—ideal where IP freedom or novel variants are needed.
High-confidence mAbs
Avoid costly rework with designs tuned for your target and structure from the start.
High affinity
Minimal off-target binding
Low cross-reactivity
Superior thermostability
Manufacturing readiness
Scientific-Guidance
Work directly with our scientific team to design antibodies for real-world use—against payloads, small molecules, or internal targets.
A Human-First, AI-Augmented Approach
Design In Silico Human Monoclonal Antibody
Contact us for a 30 minute discovery call
in silico Speed
Design human mAbs in 3–5 days using known scaffolds—ideal where IP freedom or novel variants are needed.
Scientific-Guidance
Work directly with our scientific team to design antibodies for real-world use—against payloads, small molecules, or internal targets.
High-confidence mAbs
Avoid costly rework with designs tuned for your target and structure from the start.
High affinity
Minimal off-target binding
Low cross-reactivity
Superior thermostability
Manufacturing readiness
Outstanding antibodies require to start with a scientific discussion in order to understand your challenges and scope what is possible now and on the long term.
Our head offices are in the heart of Paris and our team is globally distributed, fluent in English, French , Spanish and German.We are always open to discussing your scientific challenges and see how Fabulous Sciences can help.
Drop us a line at [email protected]
60 rue François 1er75008, ParisFrance
Engineers, Doctorates, Passion, Humans
and Beloved AI
About Us
At Fabulous Sciences, we’re on a mission to accelerate antibody design with scientific precision and computational speed.Our product uses advanced machine learning to generate antibody candidates that are optimized, patent-ready, and tailored to your goals — all reviewed by our team of scientists.From target engagement to developability, we deliver auditable, in silico insights that help you move faster, reduce risk, and make better translational decisions.We’re not just automating science — we’re collaborating with you to do it better.
Manifesto
We are a science-led, problem-driven team working to accelerate the design of better antibody therapeutics. We believe biology holds remarkable solutions—but unlocking them requires better tools, deeper insight, and closer alignment between computation and experimental science.Antibodies are one of the most powerful therapeutic modalities available today, yet designing them remains slow, costly, and often opaque. We’re here to change that. At Fabulous Sciences, we use cutting-edge AI—not as a black box, but as a partner to expert intuition—to explore design space, surface actionable hypotheses, and help teams make confident, patent-aware decisions earlier in the pipeline.Transparency and trust are at the heart of our work. We collaborate closely with our partners, adapting to scientific context rather than forcing it into one-size-fits-all pipelines. Our goal is to reduce friction, not replace scientists—to support the people solving the hard problems, not distract them.In a world where R&D timelines are tightening and biological complexity is rising, we believe the future of antibody design must be rigorous, adaptable, and deeply human. That’s the future we’re building, one molecule at a time.
ABOUT US
Founding Team
Led by a team of international experts in biology, healthcare, AI and technology.
PRIVATE AND ACADEMIC TIES
Scientific Board
More than 60 years of drug development expertise.
Charles Dumontet,
M.D., Ph.D.
Co-founder of Mablink Bioscience, acquired by Eli Lilly in 2023 for its cutting-edge antibody–drug conjugate platform.Led an INSERM translational research team for 25+ years, bridging preclinical science with clinical oncology.Investigator in numerous Phase I–III trials, with deep pharma partnerships across the development pipeline.
Heinz Hillen,
Ph.D.
Co-inventor behind major blockbusters: Enbrel, Humira, and Ambrisentan.Pioneer in Alzheimer’s drug development, designing Abeta oligomer–specific immunotherapies ("globulomers").Co-author of the Amyloid Beta Dysfunction Hypothesis (Front. Neurosci. 2019), reshaping therapeutic strategy in Alzheimer’s.
Edward F. Patz, Jr. ,
M.D.
Co-founder and CEO of Grid Therapeutics, advancing novel human derived monoclonal antibodies into clinical trials.Dr. Patz was the James and Alice Chen Distinguished Professor of Radiology, Professor in Pharmacology and Cancer Biology at Duke University, with 25+ years of leadership in lung cancer biology and early detection.200+ publications and a track record of translating academic insight into clinical-stage immunotherapies for cancer.
Website Terms and Conditions (English)
(Last updated 24 July, 2025)
1. Identification of the service provider
Fab’ulous SAS – société par actions simplifiée
RCS Paris 988 098 620 (incorporated 26 June 2025)
Registered office : 60 rue François 1er, 75008 Paris, France
Contact (legal & data) : [email protected]
2. Purpose of the Site
www.fabuloussciences.com (the “Site”) is a showcase website presenting Fab’ulous SAS’s B2B antibody‑R&D services (the “Services”). It contains no user portal, e‑commerce checkout or account system. Any commercial relationship is governed exclusively by bespoke service agreements and NDAs.
3. Acceptance of the Terms
By accessing the Site you agree to be bound by these Terms.
4. Intellectual‑property notice
All Site content (texts, graphics, logo, brand) is © Fab’ulous 2025. No licence is granted; any reuse requires written permission.
5. Disclaimer
The Site provides general corporate information only; it does not constitute medical, scientific or regulatory advice.
External links are provided “as is”; Fab’ulous is not responsible for third‑party content.
6. Liability cap
Fab’ulous’ total aggregate liability for any direct loss or damage arising out of, or in connection with, access to or use of this Site shall in no event exceed ten thousand euros (€ 10 000) per calendar year. Nothing in these Terms limits or excludes Fab’ulous’ liability for (i) death or personal injury caused by its negligence, (ii) fraud or wilful misconduct, or (iii) any liability that cannot be limited under applicable law. Indirect or consequential damages (including loss of profit, business interruption or loss of data) are expressly excluded. Separate written service agreements, where applicable, prevail over this clause for the services they govern.
7. Force‑majeure
Events outside Fab’ulous’s reasonable control (e.g. power failures, strikes) suspend performance of obligations under these Terms.
8. Governing law & jurisdiction
These Terms are governed by French law. Exclusive jurisdiction lies with the courts of Paris (Tribunaux de Paris), without prejudice to mandatory rules.
10. Amendments
Fab’ulous may amend these Terms from time to time. The updated version will be posted on this page with a new “last updated” date.
Conditions Générales d'Utilisation du Site (Français)
(Dernière mise à jour : 24 juillet 2025)
1. Identification du prestataire de services
Fab’ulous SAS – société par actions simplifiée
RCS Paris 988 098 620 (immatriculée le 26 juin 2025)
Siège social : 60 rue François 1ᵉʳ, 75008 Paris, France
Contact (juridique & données) : [email protected]
2. Objet du Site
www.fabuloussciences.com (le « Site ») est un site vitrine présentant les services B2B de R&D d’anticorps de Fab’ulous SAS (les « Services »).
Il ne comporte aucun portail utilisateur, module de paiement en ligne ni système de compte.
Toute relation commerciale est régie exclusivement par des contrats de services sur mesure et des accords de confidentialité (NDA).
3. Acceptation des Conditions
En accédant au Site, vous acceptez d’être lié par les présentes Conditions.
4. Propriété intellectuelle
L’ensemble du contenu du Site (textes, graphiques, logo, marque) est © Fab’ulous 2025.
Aucun droit de licence n’est concédé ; toute réutilisation nécessite une autorisation écrite préalable.
5. Avertissement
Le Site fournit uniquement des informations corporatives générales ; il ne constitue pas un conseil médical, scientifique ou réglementaire.
Les liens externes sont fournis « en l’état » ; Fab’ulous n’est pas responsable du contenu de tiers.
6. Limitation de responsabilité
La responsabilité totale et cumulative de Fab’ulous pour tout dommage direct résultant de l’accès ou de l’utilisation du présent Site ne saurait en aucun cas excéder dix mille euros (10 000 €) par année civile.
Rien dans les présentes Conditions ne limite ou n’exclut la responsabilité de Fab’ulous en cas :(i) de décès ou de dommages corporels causés par sa négligence,(ii) de fraude ou faute intentionnelle, ou(iii) de toute responsabilité ne pouvant être limitée en vertu du droit applicable.Les dommages indirects ou consécutifs (y compris perte de profit, interruption d’activité ou perte de données) sont expressément exclus.Les accords de services écrits conclus séparément, le cas échéant, prévalent sur la présente clause pour les prestations qu’ils régissent.
7. Force‑majeure
Les événements échappant au contrôle raisonnable de Fab’ulous (p. ex. pannes de courant, grèves) suspendent l’exécution des obligations prévues aux présentes Conditions.
8. Droit applicable et juridiction compétente
These Terms are governed by French law. Exclusive jurisdiction lies with the courts of Paris (Tribunaux de Paris), without prejudice to mandatory rules.Les présentes Conditions sont régies par le droit français.La juridiction exclusive appartient aux tribunaux de Paris (Tribunaux de Paris), sans préjudice des règles impératives applicables.
10. Modifications
Fab’ulous peut modifier les présentes Conditions à tout moment.La version mise à jour sera publiée sur cette page avec une nouvelle date de « dernière mise à jour ».
Privacy Policy (English)
(Last updated 24 July, 2025, Drafted to comply with GDPR Articles 12‑14 & CNIL guidance; scope limited to the Site.)
1. Data controller
Controller : Fab’ulous SAS – RCS Paris 988 098 620
Contact for data matters : [email protected]
Fab’ulous does not act as a data processor for website visitors; any client‑project data is handled under separate service agreements.
2. Personal data we collect
| Category | Purpose & legal basis | Retention |
|---|---|---|
| Browsing & security logs (IP address, URL visited, timestamp) | Ensuring security and integrity of the Site (legitimate interest – GDPR art. 6‑1‑f) | 12 months |
| Contact enquiries (name, email, message) | Responding to incoming questions (legitimate interest / pre‑contractual request – art. 6‑1‑f/b) | 3 years from last contact |
| Cookies / analytics | Not collected at present | N/A |
Fab’ulous does not collect special‑category data through the Site and does not use visitor data for model training.
4. Recipients & processors
| Processor | Location of processing | Transfer safeguard |
|---|---|---|
| Carrd Inc. (website hosting) | United States | 2021 SCC Modules 2 & 3 |
| Google Ireland Ltd. (Workspace email/docs) | EU Data Region (if enabled) | 2021 SCC Modules 2 & 3 + EU Data Region |
| Future compute cluster / LIMS | Detailed in Service Agreement | Detailed in Service Agreement |
5. Security measures
Traffic is secured via TLS 1.3; hosting providers hold ISO 27001 certification; access to backend consoles is restricted on a need‑to‑know basis with multi‑factor authentication.
6. Your GDPR rights
You may access, rectify, erase, restrict or object to the processing of your personal data, and request portability, by emailing [email protected]. You also have the right to lodge a complaint with the CNIL (www.cnil.fr).
7. Security measures
Industry‑standard administrative, technical and physical safeguards protect personal data.
8. Changes
We may update this Privacy Policy occasionally. Material changes will be announced on the Site alongside the revised text.
POLITIQUE DE CONFIDENTIALITÉ (FRANÇAIS)
(Dernière mise à jour : 24 juillet 2025 – rédigée conformément aux articles 12-14 du RGPD et aux lignes directrices de la CNIL ; portée limitée au Site.)
1. Responsable du traitement
Responsable : Fab’ulous SAS – RCS Paris 988 098 620
Contact pour les questions relatives aux données : [email protected]
Fab’ulous n’agit pas comme sous-traitant pour les visiteurs du Site ; toute donnée issue de projets clients est traitée dans le cadre d’accords de service distincts.
2. Données personnelles que nous collectons
| Catégorie | Finalité & base juridique | Durée de conservation |
|---|---|---|
| Journaux de navigation et de sécurité (adresse IP, URL visitée, horodatage) | Assurer la sécurité et l’intégrité du Site (intérêt légitime – art. 6-1-f RGPD) | 12 mois |
| Demandes de contact (nom, e-mail, message) | Répondre aux questions entrantes (intérêt légitime / demande pré-contractuelle – art. 6-1-f/b) | 3 ans à compter du dernier contact |
| Cookies / analytics | Non collectés actuellement | N/A |
Fab’ulous ne collecte pas de données de catégorie particulière via le Site et n’utilise pas les données des visiteurs pour l’entraînement de modèles.
4. Destinataires & sous-traitants
| Sous-traitant | Lieu de traitement | Mécanisme de transfert |
|---|---|---|
| Carrd Inc. (hébergement du site) | États-Unis | Clauses contractuelles types 2021 – Modules 2 & 3 |
| Google Ireland Ltd. (Workspace e-mail/docs) | Région de données UE (si activée) | Clauses contractuelles types 2021 – Modules 2 & 3 + Région de données UE |
| Cluster de calcul / LIMS futur | Précisé dans l’accord de service | Précisé dans l’accord de service |
5. Mesures de sécurité
Le trafic est sécurisé via TLS 1.3 ; les hébergeurs disposent de la certification ISO 27001 ; l’accès aux consoles back-end est restreint selon le besoin et protégé par une authentification multifacteur.
6. Vos droits RGPD
Vous pouvez accéder à vos données personnelles, les rectifier, les effacer, en limiter ou en refuser le traitement, et demander leur portabilité, en écrivant à [email protected].Vous avez également le droit d’introduire une réclamation auprès de la CNIL (www.cnil.fr).
7. Mesures de sécurité
Des garanties administratives, techniques et physiques conformes aux normes du secteur protègent les données personnelles.
8. Modifications
Nous pouvons mettre à jour la présente Politique de confidentialité à l’occasion. Les changements matériels seront annoncés sur le Site en même temps que la version révisée.